Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rifabutin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 3/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.72 |
| ▸ | ABCC2 | Q92887 | 2/20 | 0.72 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.72 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rifabutin SCHEMBL1813946 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL17705915 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL36044 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL28325467 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL138130 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL23106966 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL36043 | 1.00 | ABCB11 (0.72) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL7778399 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL173466 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 | |
| Rifabutin SCHEMBL155626 | 0.98 | ABCB11 (0.70) | ABCB11CHRM1PTGS1ABCC4ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20228 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748371-A1 | RIFABUTIN COMPOSITIONS AND METHOD OF MAKING | BIOVERSYS AG (CH) | 2026-05-27 | — | — | EP | claimed |
| CN-122075482-A | Use of rifamycin in the treatment of colorectal cancer | — | 2026-05-26 | — | — | CN | claimed |
| EP-4740940-A1 | POLLEN PARTICLES AS CARRIERS FOR PULMONARY DELIVERY | Universidade de Santiago de Compostela (ES) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12616708-B2 | Methods for treating pulmonary non-tuberculous mycobacterial infections | INSMED INCORPORATED (US) | 2026-05-05 | — | — | US | claimed |
| US-20260109712-A1 | RIFAMYCINS FOR NONTUBERCULOUS MYCOBACTERIA | UNIV MINNESOTA (US) | 2026-04-23 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260108571-A1 | MYCOBACTERIOPHAGE COMPOSITIONS AND RELATED METHODS | OREGON STATE UNIVERSITY (US) | 2026-04-23 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| WO-1996016652-A2 | USE OF RIFABUTIN AND A COMBINATION OF RIFABUTIN AND ATOVAQUONE IN THE TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
| WO-1996004924-A1 | IMPROVED ANTIINFECTIVE POLYOXYPROPYLENE/POLYOXYETHYLENE COPOLYMERS AND METHODS OF USE | CYTRX CORPORATION (US) | 1996-02-22 | — | — | WO | claimed |
| WO-1995033851-A2 | METHOD FOR THE DETECTION OF THE ANTIBIOTIC RESISTANCE SPECTRUM OF MYCOBACTERIUM SPECIES | INNOGENETICS N.V. (BE) | 1995-12-14 | — | — | WO | claimed |
| WO-1995025510-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ALKYLTHIOALKANOIC ACIDS OR DERIVATIVES THEREOF AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS AND AS ANTISEPTIC | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-09-28 | — | — | WO | claimed |
| WO-1995015182-A1 | ANTIINFECTIVE COMPOSITIONS AND METHODS OF USE | EMORY UNIVERSITY (US) | 1995-06-08 | — | — | WO | claimed |
| EP-0648121-A1 | USE OF RIFAMYCIN DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TOXOPLASMOSIS. | PALO ALTO MEDICAL FOUND (US) | 1995-04-19 | — | — | EP | claimed |
| WO-1994025038-A1 | USE OF RIFAMYCIN DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TOXOPLASMOSIS | PALO ALTO MEDICAL FOUNDATION (US) | 1994-11-10 | — | — | WO | claimed |
| WO-1993023016-A1 | LIPOSOMAL FORMULATIONS CONTAINING RIFAMYCINS | INSTITUTO NACIONAL DE ENGENHARIA E TECNOLOGIA INDUSTRIAL/DEPARTAMENTO DE TECNOLOGIA DE INDÚSTRIAS QUÍMICAS (PT) | 1993-11-25 | — | — | WO | claimed |
| WO-1993013774-A1 | METHODS FOR PREVENTING MYCOBACTERIAL INFECTIONS WITH RIFABUTIN | ERBAMONT, INC. (US) | 1993-07-22 | — | — | WO | claimed |
| EP-0552018-A1 | Use of Rifabutin for delaying or preventing mycobacterial infections | Erbamont Inc. (US) | 1993-07-21 | — | — | EP | claimed |